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Statin drugs have been used for more than two decades to treat hypercholesterolemia and as cardio-preventive drugs, resulting in a marked decrease in cardiovascular morbidity and mortality worldwide. Statins halt hepatic cholesterol biosynthesis by inhibiting the rate-limiting enzyme in the mevalonate pathway, hydroxymethylglutaryl-coenzyme A reductase (HMGCR). The mevalonate pathway regulates a host of biochemical processes in addition to cholesterol production. Attenuation of these pathways is likely responsible for the myriad benefits of statin therapy beyond cholesterol reduction -the so-called pleiotropic effects of statins. Chief amongst these purported effects is anti-cancer activity. A considerable body of preclinical, epidemiologic and clinical evidence shows that statins impair proliferation of breast cancer cells and reduce the risk of breast cancer recurrence. Potential mechanisms for this effect have been explored in laboratory models, but remain poorly understood and require further investigation. The number of clinical trials assessing the putative clinical benefit of statins in breast cancer is increasing. Currently, a total of 30 breast cancer/statin trials are listed at the global trial identifier website clinicaltrials.gov. Given the compelling evidence from performed trials in a variety of clinical settings, there have been calls for a clinical trial of statins in the adjuvant breast cancer setting. It would be imperative for such a trial to incorporate tumour biomarkers predictive of statin response in its design and analysis plan. Ongoing translational clinical trials aimed at biomarker discovery will help identify, which breast cancer patients are most likely to benefit from adjuvant statin therapy, and will add valuable clinical knowledge to the field.
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Breast cancer
Breast cancer is globally the most common malignancy amongst women, contributing more than 25% of the total number of new cancer cases diagnosed (www.wcrf.org). The number of breast cancer cases has steadily increased over the last few decades, although annual incidence rates vary greatly worldwide, from 19.3 per 100 000 women in Eastern Africa to 89.7 per 100 000 women in Western Europe (www.who.int). Worldwide, breast cancer ranks as the fifth most frequent cause of cancer death, and in the female population, it is the second most frequent cause of cancer death [1] . In parallel with the incidence rates for breast cancer, the prevalence of overweight and obesity has rapidly risen. Overweight/obesity is often associated with the metabolic syndrome and increases the risk of a number of diseases, including hypercholesterolemia and breast cancer [2] . Not only does overweight/obesity influence breast cancer incidence [3, 4] , it also worsens prognosis following breast cancer [5] . The epidemiological and clinically manifested linkage between overweight/obesity and breast cancer is increasingly clear [6] , although important gaps exist in our knowledge. A common comorbidity of overweight/ obesity is hypercholesterolemia, and one knowledge gap is, for example, the impact of cholesterol on the progression of breast cancer and on the effectiveness of adjuvant endocrine therapy.
Molecular basis for statin use as breast cancer therapeutic agents
Statins are routinely used to treat hyperlipidaemia, but may also have antineoplastic effects. The target for statins, HMGCR, is a transmembrane glycoprotein found in the endoplasmic reticulum in all cells.
HMGCR activity controls the mevalonate pathway, which in addition to cholesterol produces steroidbased hormones and non-sterol isoprenoids (Fig. 1 ) [7, 8] . Inhibition of hepatic HMGCR causes reduced intracellular cholesterol levels in hepatocytes. This in turn triggers up-regulation of low-density lipoprotein cholesterol (LDL-C) receptors to scavenge cholesterol from the serum to support cell growth and division. Serum levels of LDL-C consequently plummet, reducing the rate of adverse cardiovascular events in statin-treated individuals [9] . Cellular cholesterol levels and HMGCR activity are maintained via tightly regulated feedback mechanisms, whereas extracellular serum cholesterol concentrations vary [10] . In addition to reducing LDL-C production, blocking the mevalonate pathway interrupts synthesis of the isoprenoids geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) [7, 8] . Isoprenylation of proteins by GGPP and FPP enables subcellular localization and intracellular trafficking of membraneassociated proteins that are essential for the cell [11] . GGPP and FPP post-translationally prenylate a host of proteins -including the oncogene products Ras, Rac and Rho -to enable their full function [11] [12] [13] . The isoprenoids demonstrate tumour-suppressive properties as regulators of important processes in cancer such as proliferation, migration and angiogenesis [7, 14] . Comprehensive analysis of statin-induced changes in tumour cell lipid profiles may reveal the dominant pathways through which statins attenuate tumour promotion [15] .
Highly proliferative cells (such as cancer cells) must rapidly produce lipid bilayer membranes, requiring increased cholesterol biosynthesis [16] . Whilst the cholesterol biosynthesis pathway is tightly regulated in normal cells, it may be dysregulated in cancer cells [17] . It has been implied that HMGCR is a metabolic oncogene, and that dysregulation of the mevalonate pathway promotes transformation [18] . In addition, high mRNA levels of HMGCR and other mevalonate pathway genes were associated with impaired prognosis for breast cancer patients [18] . This finding was recently validated in two large breast cancer datasets [19] .
The mevalonate pathway is a possible therapeutic target for tumours with mutations of the tumour suppressor p53 [20, 21] . The p53 protein, encoded by the TP53 gene, is dubbed 'the guardian of the genome' due its tumour-suppressing activities. These activities, triggered by DNA damage, include activation of DNA repair mechanisms, initiation of growth arrest at the G1/S boundary and induction of apoptosis if repair fails. The mevalonate pathway is both necessary and sufficient for the phenotypic effects of mutant p53 on breast tissue architecture, and mutant p53 associates with sterol gene promoters [20] . In a three-dimensional culture model, mutant p53 up-regulated mevalonate pathway genes in breast cancer cells, leading to disordered, invasive morphology [20] . In the same model, depletion of mutant p53 by RNA interference caused reversion to normal morphology. Remarkably, the addition of clinically achievable concentrations of simvastatin to the culture system resulted in marked reductions in tumour cell growth, induction of apoptosis and reversion to normal morphology in the various breast cancer cell lines tested [20] . The beneficial effects of simvastatin were negated when the mevalonate pathway products GGPP and FPP were simultaneously added to the culture medium. The p53 effect is likely modulated by sterol regulatory elementbinding proteins (SREBPs), and tied to the YAP/ TAZ effectors of the Hippo signalling pathway [22] . YAP/TAZ activity is also controlled by Rho GTPases, which are dependent on prenylation for activation [23] . Therefore, overexpression of genes encoding p53, SREBPs, mevalonate pathway genes and the YAP/TAZ transcriptional regulators may identify breast tumours that will be sensitive to statin treatment.
A large number of in vitro and in vivo cancer studies with statins have been performed (Table 1) , with many more underway. So far, these models have shown that statins decrease proliferation and increase apoptosis of breast cancer cells [18, 24] . The biological mechanisms for these actions are not yet fully elucidated. Our previous work demonstrated that HMGCR is differentially expressed in human breast cancer samples and holds prognostic value [25, 26] . HMGCR may also predict tumour response to endocrine treatment [27] , as well as to statin treatment, in a recent phase II clinical trial (ClinicalTrials.gov Identifier: NCT00816244) [28] . Other in vitro studies demonstrated substantial statin-induced increases in HMGCR expression [29] , and atorvastatin induced HMGCR up-regulation when assessed with a novel, well-validated monoclonal HMGCR antibody [19] . Additionally, in vivo studies suggest that HMGCR activity is higher in mammary tumours compared with normal mammary glands, and that tumours are resistant to feedback regulation by sterols [30] .
If statins do target the mevalonate pathway in cancer cells within a tumour, the lowering of intracellular cholesterol may lead to lowered intra-tumoural autocrine hormone production, as cholesterol is fundamental for all steroid hormone synthesis. Interestingly, one study has reported that atorvastatin and its metabolites are detectable in human breast samples following oral administration [31] , indicating that direct inhibition of HMGCR may occur in breast tumours. Most relevant for an endocrine responsive disease such as oestrogen receptor (ER)-positive breast cancer, statin treatment reduces levels of the cholesterol metabolite 27-hydroxy cholesterol (27HC) [32] . 27HC acts as an ER ligand, potentiating ER-dependent tumour growth [33] [34] [35] [36] . Interestingly, 27HC can agonize both the ER and the liver X receptor (LXR) to drive breast tumour proliferation [33, 34] , and it promotes metastasis through interactions with myeloid immune cells [37] . The cholesterol biosynthesis pathway was recently shown to be up-regulated in ER-positive breast cancer cell lines that are resistant to oestrogen deprivation [38, 39] , suggesting that dysregulation of cholesterol biosynthesis may be a mechanism of endocrine resistance in hormone receptor-positive breast cancer [38, 39] . Chronic oestrogen deprivation in ER-positive breast cancer cells seems to stabilize the epigenetic activation of the mevalonate pathway and cholesterol biosynthesis [39] , and this leads to the accumulation of other ligands (such as 27HC), which potentiate ER signalling in the absence of oestrogen, consequently driving the activation of genes that promote a proliferative and invasive cell phenotype [39] .
To summarize, cancer cells depend on cholesterol for continued growth and survival. Therefore, attenuating cholesterol biosynthesis seems to be a promising anti-cancer strategy. Of note, rapidly proliferating cancer cells have an increased cholesterol demand to enable cell membrane synthesis [16, 40] . By lowering plasma levels of cholesterol and 27HC, their availability for use by cancer cells is consequently lowered. Additionally, direct inhibition of HMGCR by statins depletes intratumoural reserves of isoprenoids, which are key regulators of cancer cell proliferation and metastasis. Ongoing studies are exploring additional roles that cholesterol, cholesterol metabolites and statins play in breast tumour promotion.
Breast cancer risk reduction by statins
The positive association between overweight and obese body constitutions on risk of postmenopausal breast cancer has been demonstrated by several studies [3, 6, [41] [42] [43] . The biological underpinnings of the observed association between obesity and breast cancer are not completely understood; both in terms of effects from the local micro-environment on progression [44] , and also regarding breast cancer initiation (an area that has hardly been explored) [45] . Overweight-associated alterations in circulating cholesterol might partly explain the association between obesity and breast cancer [46] . Evidence for an association between cholesterol and cancer incidence is not consistent [47] [48] [49] . Some epidemiological studies previously indicated lower cancer incidence amongst statin users [50, 51] , although the results have been inconsistent across studies [52] [53] [54] [55] . Our recent update from the large, prospective Nurse's Health Study (NHS) showed no association between different statin exposures and risk of invasive breast cancer [56] . Results from a prominent metaanalysis were null [54] . Notably in the NHS, statin use was not associated with increased risk of invasive breast cancer, regardless of histological type. Nonetheless, development of a subset of breast cancer -presumably subtypes highly dependent on functional cholesterol metabolismmay possibly be obstructed by treatment with cholesterol-lowering agents. This hypothesis stresses the need for a much more sophisticated approach to modelling risk of breast cancer molecular subtypes.
Potential future studies of statins in relation to breast cancer incidence should explore effects in an appropriately powered primary prevention trial amongst high-risk women. Such a trial would benefit from translational studies where the biological relevance of statins to prevent breast cancer is understood. To investigate the biological processes of statins as a primary preventive drug in experimental models have yet not been investigated in relevant models involving normal breast epithelial cells and stromal cells, which will be critical for understanding the potential role of statins in breast cancer initiation, and therefore primary prevention.
Statins and breast cancer prognosis
The U.S. National Cancer Institute estimated that there were over 2. [59] . Since publication of these studies, 11 others have measured the association in a variety of source populations [60] . A systematic review and meta-analysis reported a summary relative risk associating statin use with breast cancer recurrence of 0.64 (95% CI: (0.53-0.79) [60] . Another meta-analysis showed that statin use was associated with lower breast cancer-specific mortality (lipophilic statins) and all-cause mortality (lipophilic and hydrophilic statins) [61] . A third meta-analysis of observational studies showed that postdiagnostic statin use was associated with lower cancer-specific mortality in breast cancer, and prediagnostic statin use was negatively associated with both all-cause and cancer-specific mortality [62] .
Statins and response to endocrine therapy in breast cancer
Hypercholesterolemia is an established clinical side effect of aromatase inhibitor (AI) therapy.
Given the revelations about the estrogenic cholesterol metabolite 27HC, this phenomenon may counteract the intended effects of AIs [33, 63] . Breast cancer patients experiencing hypercholesterolemia during AI treatment may thus benefit from concomitant cholesterol-lowering treatment to reduce the probability of 27HC-driven ER actions. Tamoxifen, on the other hand, reduces circulating cholesterol levels. [64] . The beneficial effects of concomitant CLM were apparent for both endocrine drug groups (AI and tamoxifen).
Since cholesterol forms the biochemical scaffold for all steroid hormones (e.g. oestradiol), it is likely to play a crucial role in hormone (oestrogen)-dependent breast cancer. Importantly, 27HC, the oxysterol produced from cholesterol, is involved in the regulation of intracellular cholesterol homeostasis [33] , but also acts as an endogenous selective oestrogen receptor modulator capable of increasing the growth and metastasis of tumours [63] . gained through collaboration with the McDonnell Lab at Duke University [32] , where biological samples from our "window-of-opportunity" statin trial [19, 28, 65] were analysed. This work demonstrated that statin therapy reduces 27HC in parallel with reductions in LDL cholesterol levels [32] . A significant up-regulation of tumour expression of CYP27A1, the enzyme responsible for the production of 27HC from cholesterol ( Fig. 1) , was, however, observed in breast tumours following statin therapy. Further investigation revealed noteworthy associations between CYP27A1 expression and adverse tumour characteristics and with poorer breast cancer prognosis in women 50 years and older (presumably postmenopausal women). The revelation that prognosis was worse for older women with high tumour CYP27A1 expression (and, presumably, high 27HC), is of relevance as these will be the breast cancer patients who are prescribed AI treatment; measures to address 27HC levels may improve outcomes for these women.
AIs have now been used in postmenopausal breast cancer treatment for more than a decade. However, updated knowledge on the interaction between endocrine treatment and obesity/hypercholesterolemia is needed to ensure that breast cancer patients with lipid-associated comorbidities, such as obesity and hypercholesterolemia, receive optimal endocrine treatment.
Predictive factors for statin response in breast cancer
The well-characterized molecular and clinical heterogeneity of breast cancer warrants that for every novel drug showing efficacy against this disease, specific treatment predictive biomarkers should be identified to enable the precise selection and treatment of only those patients who may derive clinical benefit from the treatment. As such, the search for statin treatment predictive markers in breast cancer has been the subject of many studies (Table 2) . HMGCR has been shown to be overexpressed in about 80% of breast tumours, and its expression is correlated with less aggressive tumour phenotype and longer recurrence-free survival [25] [26] [27] . In the aforementioned clinical phase II trial when 50 breast cancer patients were treated preoperatively with 80 mg day À1 atorvastatin for 2 weeks, tumour levels of Ki67 (a proliferation marker) decreased from presurgical biopsy to resected tumour only if the tumour expressed HMGCR [28, 65] , suggesting a predictive role for HMGCR for efficacy of statin treatment in breast cancer. HMGCR was not only differentially expressed across tumours from breast cancer patients, but was also associated with improved prognosis amongst ER-positive breast cancer patients, whereas ERnegative patients seemed to have better outcomes when HMGCR was absent [25, 26] . Several other mevalonate pathway biomarkers have been associated with breast tumour response to statins in vitro and in animal models. However, no study has comprehensively evaluated the network comprised of these individual factors, and how it is perturbed by statin exposure to alter recurrence risk. Randomized trials are now warranted to clarify the potential beneficial effects of statins in breast cancer management in the adjuvant and metastatic setting. In October 2016, the first trial with statins in metastatic breast cancer was launched, with the hypothesis that HMGCR expression will identify tumours that will respond to statin treatment (ClinicalTrials.gov Identifier: NCT02958852).
Exploring transcription profiles associated with breast cancer sensitivity to statin treatment is another method that has been explored to discover genes or gene signatures that are predictive of statin treatment sensitivity. In one such study based on in vitro experiments with atorvastatin in a collection of breast cancer cell lines, we aimed to uncover transcriptional differences associated with statin response in breast cancer [19, 65] . The strongest discriminants between the breast cancer cells associated with statin sensitivity at the transcriptional level were the expression of the oestrogen receptor and a gene set enriched for genes involved in the cholesterol biosynthesis pathway. Following statin treatment, the less-sensitive cells exhibited the classical response of up-regulating the expression of genes in the cholesterol biosynthesis pathway via the normal negative feedback loop resulting from the statin-induced inhibition of HMGCR. This classical response was, however, weaker in the sensitive cells, suggesting that these cells may possess an inherent defect in this pathway. This cholesterol biosynthesis gene set showed potential for identifying tumours that experience reduced proliferation upon statin treatment, albeit in a small cohort of patients. Further studies using similar and more advanced approaches are necessary to identify robust biomarkers for identifying patients most likely to derive benefit from the addition of cholesterol- [8, 66] . It would be imperative for such a trial to incorporate tumour biomarkers predictive of statin response in its design and analysis plan.
Concluding remarks
Taken together, obesity-associated metabolic disorders such as hypercholesterolemia can have a negative impact on the prognosis of breast cancer patients. This may in particular be of importance in the endocrine treatment setting. Future research activities should evaluate the interplay between host factors (e.g. obesity/hypercholesterolemia), treatment factors (e.g. statin therapy) and breast cancer progression. If such studies detect a group of patients with less expected clinical efficacy of the standard endocrine drug of choice, this may impact future clinical guidelines for the purpose of improved clinical outcome amongst breast cancer patients. Advanced understanding of the molecular mechanisms of breast cancer response to common prescription drugs such as statins stands to increase the effectiveness with which we treat breast cancer and lead to the development of new therapies with specific actions against upregulated molecular pathways.
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